[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"decision-aids\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:decision-aids":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,82,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100498909","phase-2-the-impact-of-a-patient-decision-aid-on-treatment-choices-for-patients-with-an-unexpected-malignant-colorectal-polyp-100498909",false,"NCT05776381","The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp","The Impact of an In-consultation Patient Decision Aid on Treatment Choices and Outcomes of Management for Patients With an Unexpected Malignant Colorectal Polyp A Non-randomized Clinical Phase II Study","Inclusion Criteria:\n\n* Histopathologically verified malignant colorectal polyp removed endoscopically and CT-scan (and MRI if the malignant polyp was situated in the rectum) shows N0, M0 disease.\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Inoperable due to comorbidity\n* Known residual tumor left in situ after local resection, \\>N0 or \\>M0","ALL","18 Years",{"count":19,"type":20},110,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Management of unexpected malignant colorectal polyps removed endoscopically can be challenging due to the risk of residual tumor and lymphatic spread. International studies have shown that in patients choosing surgical management instead of watchful waiting, 54-82% of bowel resections are without evidence of residual tumor or lymphatic spread. As surgical management entails risks of complications and watchful waiting management entails risks of residual disease or recurrence, a clinical dilemma arises when choosing a management strategy.\n\nShared decision making (SDM) is a concept that can be used in preference sensitive decision making to facilitate patient involvement, empowerment, and active participation in the decision making process.\n\nThis is a clinical multicenter, non-randomized, interventional phase II study involving Danish surgical departments planned to commence in the first quarter of 2024. The aim of the study is to examine whether shared decision making and using a patient decision aid (PtDA) in consultations affects patients' choice of management compared with historical data. The secondary aim is to investigate Patient Reported Experience Measures (PREMs) and Patient Reported Outcome Measures (PROMs) using questionnaire feedback directly from the patients.",[26,27,28,29,30,31],"Shared Decision Making","Colonic Polyp","Decision Aids","Rectal Polyp","Colorectal Polyp","Colorectal Cancer",[33,34,35,26],"non-randomized trial","malignant colorectal polyp","Patient Decision aid","NOT_YET_RECRUITING","2026-04-29",{"date":39,"type":40},"2026-04-30","ACTUAL",{"date":42,"type":20},"2028-02-01",{"date":44,"type":20},"2033-02-01",{"name":46,"class":47},"Vejle Hospital","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100605853","developing-an-innovative-decision-support-tool-for-pediatric-neuromuscular-scoliosis-100605853","NCT07167927","Developing an Innovative Decision Support Tool for Pediatric Neuromuscular Scoliosis","Developing an Innovative Decision Support Tool for Pediatric Neuromuscular Scoliosis - Aims 2 and 3","Inclusion criteria:\n\n* Parent-child dyads of children with neuromuscular scoliosis who speak English and Spanish.\n* Child is between ages 8-21 years of age and they are coming into the pediatric orthopaedic surgery clinic for consultation about potential surgery for NMS.\n* NMS is defined as having neurologic impairment (NI) and scoliosis using relevant ICD-9 or ICD-10 codes from Feudtner, et al. 2014 or Berry, et al. 2012. or a qualifying diagnosis per the Pediatric Spine Study Group definition of NMS.\n* All pediatric orthopaedic surgeons and neurosurgeons who treat neuromuscular scoliosis at our study sites will be eligible participants.\n\nExclusion criteria:\n\n* Families whose child with NMS is less than 8 years of age at time of orthopaedic consultation because surgery at a younger age usually indicates an atypical case.\n* Children with the diagnosis of Duchenne's or Becker's muscular dystrophy due to potential disease modifying therapies that may alter curve progression.","8 Years",{"count":19,"type":20},[58],"NA","The goal of this pilot hybrid type I efficacy\u002Fimplementation trial is to assess a newly developed decision support tool patients, parents, and providers to use during surgical treatment decision making for neuromuscular scoliosis (NMS). Results from this pilot will inform the design of a future larger effectiveness trial of the decision support tool.\n\nParticipants will either receive usual care or receive the decision support tool. Researchers will assess the decision made, decision quality, individual affective, cognitive, and behavioral effects, and feasibility and acceptability of tool use. They will also collect potential barriers and facilitators to implementation and feedback about the tool and study design to maximize likelihood of successful deployment of the tool into clinical practice and inform the design of a future trial. The outcomes measures will be used to inform potential effect size estimates to inform a future trial.",[61,62,63,26,64,28],"Children With Medical Complexity (CMC)","Multiple Chronic Conditions","Neuromuscular Scoliosis","Decision Support Systems, Clinical",[66,67,68,69,70],"children with medical complexity","shared decision making","values clarification","uncertainty communication","decision support tool","RECRUITING","2025-12-04",{"date":74,"type":40},"2025-12-05",{"date":76,"type":40},"2025-10-21",{"date":78,"type":20},"2027-03-31",{"name":80,"class":47},"University of Utah",2,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100565165","decision-aid-for-dementia-therapies-100565165","NCT06638632","Decision Aid for Dementia Therapies","Helping Patients, Families, and Clinicians Make Shared Decisions About Therapies for Dementia","Inclusion Criteria:\n\nPatients:\n\n* UCHealth patient\n* Ages 18 y\u002Fo and above\n* Documented neurocognitive deficits suggestive of mild cognitive impairment or early dementia as determined by their treating clinician.\n* English or Spanish speaking\n\nCaregiver:\n\n* Ages 18 y\u002Fo and above\n* Identified by the study participant as the person who helps the most with their medical care outside the hospital or clinic.\n* English or Spanish speaking\n\nClinicians:\n\n* Neurologists, primary care clinicians, pharmacists, or psychologists involved in dementia decision-making.\n* English or Spanish speaking\n\nExclusion Criteria:\n\nPatients:\n\n* Not English or Spanish-speaking\n* Neurocognitive deficits suggestive of moderate or severe cognitive impairment or late stage dementia.\n* Not able to consent for themselves\n\nCaregiver:\n\n* Ages 17 y\u002Fo and below\n* Not English or Spanish-speaking\n\nClinicians:\n\n* Neurologists, primary care clinicians, pharmacists, or psychologists involved in dementia decision-making.\n* English or Spanish-speaking",true,{"count":91,"type":20},100,[58],"The purpose of this study is to develop a decision aid to support patients and families making decisions about medications for dementia.",[95,28],"Dementia",[97],"Lecanemab","2025-09-12",{"date":100,"type":40},"2025-09-16",{"date":102,"type":20},"2025-11",{"date":104,"type":20},"2026-02-28",{"name":106,"class":47},"University of Colorado, Denver",1,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":21,"phases":119,"briefSummary":120,"conditions":121,"keywords":126,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":107},"100566135","decision-support-intervention-of-minor-cancer-patients-and-their-parents-100566135","NCT06651242","Decision Support Intervention of Minor Cancer Patients and Their Parents","Effectiveness Evaluation on the Decision Preferences and Decision Support Intervention of Minor Cancer Patients and Their Parents","Inclusion Criteria:\n\n* Inclusion Criteria for Parents:\n\n  1. Age over 20 years.\n  2. Child under 20 years old, diagnosed with cancer by a doctor.\n  3. their child know her\u002Fhis cancer diagnosis.\n  4. Agree to have the child participate in family meeting and have ability to communicate in Mandarin or Taiwanese.\n* Inclusion Criteria for Minors:\n\n  1. Aged between 7 and 20 years, diagnosed with pediatrtic cancer.\n  2. Aware of their cancer diagnosis.\n  3. Able to express their thoughts to the researcher in Mandarin or Taiwanese.\n  4. Both the minor and their legal guardian consent to participate in the study.\n\nExclusion Criteria:\n\n1. Diagnosed with depression, and\u002For anxiety, and\u002For other mental disorders.\n2. Legal guardian is unwilling to inform the minor of their diagnosis.\n3. Minor is unwilling to share their thoughts with their parents.","7 Years","20 Years",{"count":118,"type":20},80,[58],"The purpose of this stuidy are: (1) to explore the information needs of parents having children with cancer when making treatment decisions; (2) to develop a Taiwan version of the Control Preferences Scale for decision support aids; (3) to implement and evaluate the effectiveness of involving minor cancer patients and their parents in treatment decision-making.",[122,123,28,124,125],"Pediatric Cancer","Adolescent Health","Parents of Children With Cancer","Decision Making ,Shared",[127,128,129,130,131],"Minor Cancer","Parents","Decision Preferences","Decision Support","Intervention","2025-08-26",{"date":134,"type":40},"2025-08-28",{"date":136,"type":40},"2022-10-26",{"date":138,"type":20},"2027-07-31",{"name":140,"class":47},"Kaohsiung Medical University Chung-Ho Memorial Hospital"]